{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T09:41:24Z","timestamp":1789897284060,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ygyno.2017.01.016","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T14:34:44Z","timestamp":1484750084000},"page":"486-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers"],"prefix":"10.1016","volume":"144","author":[{"given":"Kim A.","family":"Reiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Fyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Brade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Milosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Scardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hacker-Prietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Temkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Horiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Anne","family":"Stayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer S.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2017.01.016_bb0005","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-1552","article-title":"A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis","volume":"21","author":"Reiss","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2017.01.016_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0936-6555(03)00223-1","article-title":"Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target","volume":"16","author":"Chalmers","year":"2004","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"10","key":"10.1016\/j.ygyno.2017.01.016_bb0015","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1096\/fj.06-5916fje","article-title":"Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan\/temozolomide efficacy against colon carcinoma","volume":"20","author":"Tentori","year":"2006","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.ygyno.2017.01.016_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jnci\/djh005","article-title":"Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361","volume":"96","author":"Calabrese","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.ygyno.2017.01.016_bb0025","first-page":"371","article-title":"Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor","volume":"2","author":"Miknyoczki","year":"2003","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2017.01.016_bb0030","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2011.05.084","article-title":"The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy","volume":"99","author":"Nowsheen","year":"2011","journal-title":"Radiother. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2017.01.016_bb0035","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1158\/1078-0432.CCR-06-2872","article-title":"Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models","volume":"13","author":"Albert","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ygyno.2017.01.016_bb0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MNM.0b013e32834a369b","article-title":"Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma","volume":"32","author":"Schaefer","year":"2011","journal-title":"Nucl. Med. Commun."},{"issue":"4","key":"10.1016\/j.ygyno.2017.01.016_bb0045","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ijrobp.2008.07.031","article-title":"Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential","volume":"72","author":"Dungey","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2017.01.016_bb0050","series-title":"2011 Gastrointestinal Cancers Symposium","article-title":"Effect of inhibition of poly-(ADP ribose) polymerase on gemcitabine and radiation-induced cytotoxicity of pancreatic cancer cells","author":"Tuli","year":"2011"},{"issue":"1","key":"10.1016\/j.ygyno.2017.01.016_bb0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2006.11.045","article-title":"Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm","volume":"68","author":"Regine","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.016_bb0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ygyno.2010.10.018","article-title":"Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the gynecologic oncology group","volume":"120","author":"Kunos","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2017.01.016_bb0065","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.016_bb0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"282","key":"10.1016\/j.ygyno.2017.01.016_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"issue":"4","key":"10.1016\/j.ygyno.2017.01.016_bb0080","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.016_bb0085","doi-asserted-by":"crossref","first-page":"187-+","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression Models and Life-Tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"issue":"7035","key":"10.1016\/j.ygyno.2017.01.016_bb0090","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ygyno.2017.01.016_bb0095","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2017.01.016_bb0100","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/sj.bjc.6602606","article-title":"Targeted antitumour therapy - future perspectives","volume":"92","author":"Ranson","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"15","key":"10.1016\/j.ygyno.2017.01.016_bb0105","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2017.01.016_bb0110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly (ADP-ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2017.01.016_bb0115","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2017.01.016_bb0120","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817300604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817300604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T22:00:49Z","timestamp":1719007249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817300604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0090825817300604"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.01.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}